Accueil > Plan du site > partie 11

Date de mise à jour : 25/04/2001

Mise en page : Xavier et Angéline





XI. Références bibliographiques


1. OMS, editor. Organisation Mondiale de la Santé; Internet :

2. Katz J. Scoring systems for measuring progression of visual field loss in clinical trials of glaucoma treatment. Ophthalmology 1999;106(2):391-395.

3. Menu, Corbe. Stimulus visuel et différentes fonctions visuelles. In. Encycl. Méd. Chir (Paris),Ophtalmologie,21027 A 20; 1991. p. 26.

4. Crépy, Maille. Physiologie, examen clinique et pathologie de la vision des couleurs. In. Encycl. Méd. Chir (Paris),Ophtalmologie,21-030-B-10; 1997. p. 14.

5. Nordmann J-P. Sensibilité au contraste. In. Encycl. Méd. Chir (Paris),Ophtalmologie, 21045 A30; 1991. p. 4.

6. Le Gargasson J-F, Rigaudière F. Explorations électrophysiologiques sensorielles (ERG, EOG, PEV). In. Encycl. Méd. Chir (Paris),Ophtalmologie, 21046 A10; 1993. p. 8.

7. Elliott DB, Patla A, Bullimore MA. Improvements in clinical and functional vision and perceived visual disability after first and second eye cataract surgery. Br J Ophthalmol 1997;81:889-895.

8. McClure ME, Hart PM, Jackson AJ, Stevenson MR, Chakravarthy U. Macular degeneration: do conventional measurements of impaired visual function equate with visual disability? Br J Ophthalmol 2000;84:244-250.

9. Hazel CA, Petre KL, Armstrong RA, Benson MT, Frost NA. Visual function and subjective quality of life compared in subjects with acquired macular disease. Invest Ophthalmol Vis Sci 2000;41(6):1309-1315.

10. Brown GC, Brown MM, Sharma S. Difference between ophthalmologists' and patients' perceptions of quality of life associated with age-related macular degeneration. Can J Ophthalmol 2000;35(3):127-133.

11. Hart PM, Chakravarthy U, Stevenson MR. Questionnaire-based survey on the importance of quality of life measures in ophthalmic practice. Eye 1998;12(( Pt 1)):124-126.

12. Scott IU, Schein OD, West S, Bandeen-Roche K, Enger C, Folstein MF. Functional status and quality of life measurement among ophthalmic patients. Arch Ophthalmol 1994;112(3):329-335.

13. Mills RP. Correlation of quality of life with clinical symptoms and signs at the time of glaucoma diagnosis. Trans Am Ophthalmol Soc 1998;96:753-812.

14. Alonso J, Espallargues M, Andersen TF, Cassard SD, Dunn E, Bernth-Petersen P, et al. International applicability of the VF-14. An index of visual function in patients with cataracts. Ophthalmology 1997;104(5):799-807.

15. Castells X, Alonso J, Ribo C, Casado A, Buil JA, Badia M, et al. Comparison of the results of first and second cataract eye surgery. Ophthalmology 1999;106(4):676-682.

16. Damiano AM, Steinberg EP, Cassard SD, Bass EB, Diener-West M, Legro MW, et al. Comparison of generic versus disease-specific measures of functional impairment in patients with cataract. Med Care 1995;33(4 Suppl):AS120-130.

17. Desai P, Reidy A, Minassian DC, Vafidis G, Bolger J. Gains from cataract surgery: visual function and quality of life. Br J Ophthalmol 1996;80(10):868-873.

18. Espallargues M, Alonso J. Effectiveness of cataract surgery in Barcelona, Spain site results of an international study. Barcelona I-PORT investigators. International Patient Outcomes Research Team. J Clin Epidemiol 1998;51(10):843-852.

19. Jayamanne DG, Allen ED, Wood CM, Currie S. Correlation between early, measurable improvement in quality of life and speed of visual rehabilitation after phacoemulsification. J Cataract Refract Surg 1999;25(8):1135-1139.

20. Wilson MR, Coleman AL, Yu F, Bing EG, Sasaki IF, Berlin K, et al. Functional status and well-being in patients with glaucoma as measured by the Medical Outcomes Study Short Form-36 questionnaire. Ophthalmology 1998;105(11):2112-2116.

21. Mangione CM, Phillips RS, Lawrence MG, Seddon JM, Orav EJ, Goldman L. Improved visual function and attenuation of declines in health-related quality of life after cataract extraction. Arch Ophthalmol 1994;112(11):1419-1425.

22. Scott IU, Smiddy WE, Schiffman J, Feuer WJ, Pappas CJ. Quality of life of low-vision patients and the impact of low-vision services. Am J Ophthalmol 1999;128(1):54-62.

23. Mangione CM, Gutierrez PR, Lowe G, Orav EJ, Seddon JM. Influence of age-related maculopathy on visual functioning and health-related quality of life. Am J Ophthalmol 1999;128(1):45-53.

24. Sherwood MB, Garcia-Siekavizza A, Meltzer MI, Hebert A, Burns AF, McGorray S. Glaucoma's impact on quality of life and its relation to clinical indicators. A pilot study [see comments]. Ophthalmology 1998;105(3):561-566.

25. Wandell PE, Lundstrom M, Brorsson B, Aberg H. Quality of life among patients with glaucoma in Sweden. Acta Ophthalmol Scand 1997;75(5):584-588.

26. Boisjoly H, Gresset J, Fontaine N, Charest M, Brunette I, LeFrancois M, et al. The VF-14 index of functional visual impairment in candidates for a corneal graft. Am J Ophthalmol 1999;128(1):38-44.

27. Cassard SD, Patrick DL, Damiano AM, Legro MW, Tielsch JM, Diener-West M, et al. Reproducibility and responsiveness of the VF-14. An index of functional impairment in patients with cataracts. Arch Ophthalmol 1995;113(12):1508-1513.

28. Linder M, Chang TS, Scott IU, Hay D, Chambers K, Sibley LM, et al. Validity of the visual function index (VF-14) in patients with retinal disease. Arch Ophthalmol 1999;117(12):1611-1616.

29. Parrish RK, 2nd, Gedde SJ, Scott IU, Feuer WJ, Schiffman JC, Mangione CM, et al. Visual function and quality of life among patients with glaucoma. Arch Ophthalmol 1997;115(11):1447-1455.

30. Gutierrez P, Wilson MR, Johnson C, Gordon M, Cioffi GA, Ritch R, et al. Influence of glaucomatous visual field loss on health-related quality of life. Arch Ophthalmol 1997;115(6):777-784.

31. Brahma A, Ennis F, Harper R, Ridgway A, Tullo A. Visual function after penetrating keratoplasty for keratoconus: a prospective longitudinal evaluation. Br J Ophthalmol 2000;84(1):60-66.

32. Uusitalo RJ, Brans T, Pessi T, Tarkkanen A. Evaluating cataract surgery gains by assessing patients' quality of life using the VF-7. J Cataract Refract Surg 1999;25(7):989-994.

33. Parrish RK, 2nd. Visual impairment, visual functioning, and quality of life assessments in patients with glaucoma. Trans Am Ophthalmol Soc 1996;94:919-1028.

34. Cole SR, Beck RW, Moke PS, Gal RL, Long DT. The National Eye Institute Visual Function Questionnaire: experience of the ONTT. Optic Neuritis Treatment Trial. Invest Ophthalmol Vis Sci 2000;41(5):1017-1021.

35. Mangione CM, Lee PP, Pitts J, Gutierrez P, Berry S, Hays RD. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators. Arch Ophthalmol 1998;116(11):1496-1504.

36. Yu Q, Li S, Chen H, Ye T, Ao J. Development of the scale of quality of life for diseases with visual impairment. Yen Ko Hsueh Pao 1996;12(1):36-39.

37. Carta A, Braccio L, Belpoliti M, Soliani L, Sartore F, Gandolfi SA, et al. Self-assessment of the quality of vision: association of questionnaire score with objective clinical tests. Curr Eye Res 1998;17(5):506-511.

38. Frost NA, Sparrow JM, Durant JS, Donovan JL, Peters TJ, Brookes ST. Development of a questionnaire for measurement of vision-related quality of life. Ophthalmic Epidemiol 1998;5(4):185-210.

39. Keeffe JE, McCarty CA, Hassell JB, Gilbert AG. Description and measurement of handicap caused by vision impairment. Aust N Z J Ophthalmol 1999;27(3-4):184-186.

40. Pesudovs K, Coster DJ. An instrument for assessment of subjective visual disability in cataract patients. Br J Ophthalmol 1998;82:616-624.

41. Lawrence DJ, Brogan C, Benjamin L, Pickard D, Stewart-Brown S. Measuring the effectiveness of cataract surgery: the reliability and validity of a visual function outcomes instrument. Br J Ophthalmol 1999;83(1):66-70.

42. Lundstrom M, Roos P, Jensen S, Fregell G. Catquest questionnaire for use in cataract surgery care: description, validity, and reliability. J Cataract Refract Surg 1997;23(8):1226-1236.

43. Crabtree HL, Hildreth AJ, O'Connell JE, Phelan PS, Allen D, Gray CS. Measuring visual symptoms in British cataract patients: the cataract symptom scale [see comments]. Br J Ophthalmol 1999;83(5):519-523.

44. Lum F, Schein O, Schachat AP, Abbott RL, Hoskins HD, Jr., Steinberg EP. Initial two years of experience with the AAO National Eyecare Outcomes Network (NEON) cataract surgery database. Ophthalmology 2000;107(4):691-697.

45. Lee BL, Gutierrez P, Gordon M, Wilson MR, Cioffi GA, Ritch R, et al. The Glaucoma Symptom Scale. A brief index of glaucoma-specific symptoms. Arch Ophthalmol 1998;116(7):861-866.

46. Terwee CB, Gerding MN, Dekker FW, Prummel MF, Wiersinga WM. Development of a disease specific quality of life questionnaire for patients with Graves' ophthalmopathy: the GO-QOL. Br J Ophthalmol 1998;82(7):773-779.

47. Barber BL, Strahlman ER, Laibovitz R, Guess HA, Reines SA. Validation of a questionnaire for comparing the tolerability of ophthalmic medications [published erratum appears in Ophthalmology 1997 May;104(5):736, 890-3]. Ophthalmology 1997;104(2):334-342.

48. Vitale S, Schein OD, Meinert CL, Steinberg EP. The refractive status and vision profile: a questionnaire to measure vision-related quality of life in persons with refractive error. Ophthalmology 2000;107(8):1529-1539.

49. Hart PM, Chakravarthy U, Stevenson MR, Jamison JQ. A vision specific functional index for use in patients with age related macular degeneration. Br J Ophthalmol 1999;83:1115-1120.

50. Wolffsohn JS, Cochrane AL, Watt NA. Implementation methods for vision related quality of life questionnaires. Br J Ophthalmol 2000;84(9):1035-1040.

51. Brown GC, Sharma S, Brown MM, Kistler J. Utility values and age-related macular degeneration. Arch Ophthalmol 2000;118(1):47-51.

52. Brown GC. Vision and quality-of-life. Trans Am Ophthalmol Soc 1999;97:473-511.

53. Brown MM, Brown GC, Sharma S, Garrett S. Evidence-based medicine, utilities, and quality of life. Curr Opin Ophthalmol 1999;10(3):221-226.

54. Brown GC, Brown MM, Sharma S, Brown HC. Patient perceptions of quality-of-life associated with bilateral visual loss. Int Ophthalmol 1998;22(5):307-312.

55. Khan, Leibowitz, Ganley. The Framingham Eye Study. I. Outline and major prevalence findings. Am J Epidemiol 1977;106:17-.

56. Denis P, Sellem E. Pharmacologie des médications antiglaucomateuses. In. Encycl. Méd. Chir (Paris),Ophtalmologie, 21280 D20; 1998. p. 11.

57. Béchetoille A. Lasers et glaucomes chroniques de l'adulte. In. Les glaucomes, volume 2, A. Béchetoille, Ed. Jappenard (Anger-Paris); 2000. p. 357-366.

58. Béchetoille A. Chirurgie des glaucomes chroniques de l'adulte. In. Les glaucomes, volume 2, A. Béchetoille, Ed. Jappenard (Anger-Paris); 2000. p. 279-325.

59. Musch DC, Lichter PR, Guire KE, Standardi CL. The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology 1999;106(4):653-662.

60. Gordon MO, Kass MA. The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol 1999;117(5):573-583.

61. Bour T, Blanchard F, Segal A. [Therapeutic observance and life of patients with primary open-angle glaucoma. Apropos of 341 cases in the department of Marne]. J Fr Ophtalmol 1993;16(6-7):380-391.

62. Kosoko O, Quigley HA, Vitale S, Enger C, Kerrigan L, Tielsch JM. Risk factors for noncompliance with glaucoma follow-up visits in a residents' eye clinic. Ophthalmology 1998;105(11):2105-2111.

63. Busche S, Gramer E. [Improved eyedrop administration and compliance in glaucoma patients. A clinical study]. Klin Monatsbl Augenheilkd 1997;211(4):257-262.

64. Levrat, Pisella, Baudouin. Tolérance oculaire des collyres antiglaucomateux. réflexions ophtalmologiques 2000;5(33):27-23.

65. Demailly P, Zoute C, Castro D. [Personalities and chronic glaucoma]. J Fr Ophtalmol 1989;12(8-9):595-601.

66. Duch S, Duch C, Pasto L, Ferrer P. Changes in depressive status associated with topical beta-blockers. Int Ophthalmol 1992;16(4-5):331-335.

67. Erb C, Batra A, Lietz A, Bayer AU, Flammer J, Thiel HJ. Psychological characteristics of patients with normal-tension glaucoma. Graefes Arch Clin Exp Ophthalmol 1999;237(9):753-757.

68. Erb C, Batra A, Bromer A, Bayer AU, Muller-Schaaf B, Thiel HJ. [Psychiatric manifestations in patients with primary open-angle glaucoma]. Ophthalmologe 1993;90(6):635-639.

69. Fitzgerald RG. Reactions to blindness. An exploratory study of adults with recent loss of sight. Arch Gen Psychiatry 1970;22(4):370-379.

70. Barber BL, Santanello NC. Relating spontaneous adverse experience reports to scores on a questionnaire querying tolerability. Int J Clin Pharmacol Ther 1995;33(11):598-604.

71. Perfetti S, Varotto A, Massagrandi S, Pagliani F, Bonomi L. Glaucoma and quality of the life. Acta Ophthalmol Scand Suppl 1998;227:52.

72. Javitt JC, Schiffman RM. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular t hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I [In Process Citation]. J Glaucoma 2000;9(3):224-234.

73. Lee DA. Efficacy of brimonidine as replacement therapy in patients with open-angle glaucoma or ocular hypertension. Clin Ther 2000;22(1):53-65.

74. Ponticello GS, Sugrue MF, Plazonnet B, Durand-Cavagna G. Dorzolamide, a 40-year wait. From an oral to a topical carbonic anhydrase inhibitor for the treatment of glaucoma. Pharm Biotechnol 1998;11:555-574.

75. Strohmaier K, Snyder E, Adamsons I. A multicenter study comparing dorzolamide and pilocarpine as adjunctive therapy to timolol: patient preference and impact on daily life. J Am Optom Assoc 1998;69(7):441-451.

76. Hiller, Sperduto, Ederer. Epidemiologic associations with cataract in the 1971&endash;1972 National Health and Nutrition Examination Survey. Am J Epidemiol 1983;118:239.

77. Frost NA, Sparrow JM. Use of vision tests in clinical decision making about cataract surgery: results of a national survey. Br J Ophthalmol 2000;84:432-434.

78. He M, Xu J, Li S, Wu K, Munoz SR, Ellwein LB. Visual acuity and quality of life in patients with cataract in Doumen County, China. Ophthalmology 1999;106(8):1609-1615.

79. Javitt JC, Steinberg EP, Sharkey P, Schein OD, Tielsch JM, Diener M, et al. Cataract surgery in one eye or both. A billion dollar per year issue. Ophthalmology 1995;102(11):1583-1592; discussion 1592-1583.

80. Shuttleworth, Luhishi, Harrad. Do patients with age related maculopathy and cataract benefit from cataract surgery? Br J Ophthalmol 1998;82:611-616.

81. Munier A, Gunning T, Kenny D, O'Keefe M. Causes of blindness in the adult population of the Republic of Ireland. Br J Ophthalmol 1998;82(6):630-633.

82. Munoz B, West SK, Rubin GS, Schein OD, Quigley HA, Bressler SB, et al. Causes of blindness and visual impairment in a population of older Americans: The Salisbury Eye Evaluation Study. Arch Ophthalmol 2000;118(6):819-825.

83. Salive ME, Guralnik J, Christen W, Glynn RJ, Colsher P, Ostfeld AM. Functional blindness and visual impairment in older adults from three communities. Ophthalmology 1992;99(12):1840-1847.

84. Lundstrom M, Stenevi U, Thorburn W. Cataract surgery in the very elderly. J Cataract Refract Surg 2000;26(3):408-414.

85. Steinberg EP, Tielsch JM, Schein OD, Javitt JC, Sharkey P, Cassard SD, et al. National study of cataract surgery outcomes. Variation in 4-month postoperative outcomes as reflected in multiple outcome measures [see comments]. Ophthalmology 1994;101(6):1131-1140; discussion 1140-1131.

86. Steinberg EP, Tielsch JM, Schein OD, Javitt JC, Sharkey P, Cassard SD, et al. The VF-14. An index of functional impairment in patients with cataract. Arch Ophthalmol 1994;112(5):630-638.

87. Javitt JC, Wang F, Trentacost DJ, Rowe M, Tarantino N. Outcomes of cataract extraction with multifocal intraocular lens implantation: functional status and quality of life. Ophthalmology 1997;104(4):589-599.

88. Lundstrom M, Stenevi U, Thorburn W, Roos P. Catquest questionnaire for use in cataract surgery care: assessment of surgical outcomes. J Cataract Refract Surg 1998;24(7):968-974.

89. Brenner MH, Curbow B, Javitt JC, Legro MW, Sommer A. Vision change and quality of life in the elderly. Response to cataract surgery and treatment of other chronic ocular conditions. Arch Ophthalmol 1993;111(5):680-685.

90. Schein OD, Steinberg EP, Cassard SD, Tielsch JM, Javitt JC, Sommer A. Predictors of outcome in patients who underwent cataract surgery. Ophthalmology 1995;102(5):817-823.

91. Pokharel GP, Regmi G, Shrestha SK, Negrel AD, Ellwein LB. Prevalence of blindness and cataract surgery in Nepal [see comments]. Br J Ophthalmol 1998;82(6):600-605.

92. Oliver JE, Thulasiraj RD, Rahmathullah R, Baburajan, Katz J, Tielsch JM, et al. Vision-specific function and quality of life after cataract extraction in south India. J Cataract Refract Surg 1998;24(2):222-229.

93. Fletcher A, Vijaykumar V, Selvaraj S, Thulasiraj RD, Ellwein LB. The Madurai Intraocular Lens Study. III: Visual functioning and quality of life outcomes [see comments]. Am J Ophthalmol 1998;125(1):26-35.

94. Javitt JC, Brenner MH, Curbow B, Legro MW, Street DA. Outcomes of cataract surgery. Improvement in visual acuity and subjective visual function after surgery in the first, second, and both eyes. Arch Ophthalmol 1993;111(5):686-691.

95. Elliott DB, Patla AE, Furniss M, Adkin A. Improvements in clinical and functional vision and quality of life after second eye cataract surgery. Optom Vis Sci 2000;77(1):13-24.

96. Laidlaw DA, Harrad RA, Hopper CD, Whitaker A, Donovan JL, Brookes ST, et al. Randomised trial of effectiveness of second eye cataract surgery. Lancet 1998;352(9132):925-929.

97. Brydon KW, Tokarewicz AC, Nichols BD. AMO array multifocal lens versus monofocal correction in cataract surgery. J Cataract Refract Surg 2000;26(1):96-100.

98. Lundstrom, Stenevi, Thorburn. Outcome of cataract surgery considering the preoperative situation: a study of possible predictors of the functional outcome. Br J Ophthalmol 1999;83:1272-1276.

99. Fagerstrom R. Correlations of memory and learning with vision in aged patients before and after a cataract operation. Psychol Rep 1992;71(3 Pt 1):675-686.

100. Soubrane G, Coscas G. Dégénérescence maculaire liée à l'âge. In. Encycl. Méd. Chir (Paris),Ophtalmologie, 21249 A20; 1998. p. 29.

101. Sarraf D, Gin T, Yu F, Brannon A, Owens SL, Bird AC. Long-term drusen study. Retina 1999;19(6):513-519.

102. Bressler, Maguire, Bressler, Fine. Macular Photocoagulation Study Group: Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. Arch Ophthalmol 1990;108:1442-1447.

103. American Academy of Ophthalmology. Macular translocation. Ophthalmology 2000;107(5):1015-1018.

104. Chong V, Bird AC. Alternative therapies in exsudative age related macular degeneration. Br J Ophthalmol 1998;82:1441-1443.

105. Delcourt C, Diaz JL, Ponton-Sanchez A, Papoz L. Smoking and age-related macular degeneration. The POLA Study. Pathologies Oculaires Liees a l'Age. Arch Ophthalmol 1998;116(8):1031-1035.

106. Mauget-Faysse M, Coquard R, Francais-Maury C, Milea D, Chiquet C, Martin P, et al. [Radiotherapy for age-related macular degeneration: risk factors of complications, prevention and treatment of side-effects]. J Fr Ophtalmol 2000;23(2):127-136.

107. Mauget-Faysse M, Chiquet C, Milea D, Romestaing P, Gerard JP, Martin P, et al. Long term results of radiotherapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 1999;83:923-928.

108. TAP Study group. Photodynamic therapy of sufoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One year results of 2 randomiezd clinical trials-TAP report 1. Arch Ophthalmol 1999;117(10):1329-1345.

109. Schmidt-Erfurth U, Miller JW, Sickenberg M, Laqua H, Barbazetto I, Gragoudas ES, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study [comment] [see comments] [published erratum appears in Arch Ophthalmol 2000 Apr;118(4):488]. Arch Ophthalmol 1999;117(9):1177-1187.

110. Glacet-Bernard A, Kuhn D, Coscas F, Coscas G, Soubrane G. [Translocation of the macula for management of subfoveal choroidal neovascularization: first results] [In Process Citation]. J Fr Ophtalmol 2000;23(6):576-581.

111. Corbe C, Diard JP, Cohen SY, Orssaud C, Dauxerre C, Delhost B, et al. Basse vision et malvoyance (en dehors des aides optiques et de la prise en charge sociale. In. Encycl. Méd. Chir (Paris),Ophtalmologie, 21850 E15; 1999. p. 7.

112. Sellier J, Albert R, Deconinck H, Verougstraete C. [Evaluation and utilization of home visual aids prescribed to the satisfaction of the patients for age-related macular degeneration]. Bull Soc Belge Ophtalmol 1999;273:33-39.

113. Harper R, Doorduyn K, Reeves B, Slater L. Evaluating the outcomes of low vision rehabilitation. Ophthalmic Physiol Opt 1999;19(1):3-11.

114. Applegate, Sunness, Haselwood. Visual symptoms associated with geographic atrophy from age-related macular degeneration. Invest Ophthalmol Vis Sci 1996;37(3):112-.

115. Sunness, Ruben, al Ae. Visual function abnormalities and prognosis in eyes with age-related geographic atrophy of the macula and good visual acuity. Ophthalmology 1997;104:1677-1691.

116. Williams RA, Brody BL, Thomas RG, Kaplan RM, Brown SI. The psychosocial impact of macular degeneration. Arch Ophthalmol 1998;116(4):514-520.

117. Buchholz WM. Assessments of quality of life (correspondence). N Engl J Med 1996;335:520.





Haut de page



Accueil > Plan du site > partie 11